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20% patients from a younger age group i.e. 25 e 35 years. Mean 39
% of patients with newly diagnosed hypertension are uncon-
trolled with monotherapy. Among the overall patients receiving
antihypertensive therapy mean 53 % of patients are prescribed an
ARB. About 75% & 61% of doctors prefer Olmesartan as the ARB of
choice in young & elderly patients with newly diagnosed hyper-
tension, respectively. 84.79 % of doctors are of the opinion that
Olmesartan would provide early control of blood pressure as
compared to other ARBs. Combination of ARB+Diuretic is most
commonly preferred by doctors for patients with stage 2 hyper-
tension whereas ARB+CCB for diabetic hypertensive patients. In
our study, ARBs had least rate of adverse event & discontinuation
among all anti-hypertensive groups of drugs.
Conclusion: This study recognizes the pattern of presentation of
hypertension in general population and the current trends in
utilization of antihypertensive therapy. Majority of hypertensive
patients are uncontrolled with monotherapy. Angiotensin recep-
tor blockers are the preferred class of drugs with least adverse
event rate and maximum compliance.
Assessment of safety of fixed dose combination of
Olmesartan, Amlodipine andHydrochlorothiazide:
A prescription event monitoring study
Rishi Jain, Amit Bhargava
Glenmark Pharmaceuticals, Mumbai, India
Objective: A post marketing Prescription-Event Monitoring study
was undertaken to assess the safety of FDC of Olmesartan,
Amlodipine and Hydrochlorothiazide, in real world clinical set-
tings in India.
Methods: Physicians were sent PEM forms requesting clinical
event data on patients prescribed FDC of Olmesartan (20/40mg),
Amlodipine (5mg) and hydrochlorothiazide (12.5mg). Data on pa-
tient’s demographics, indication for FDC, concomitantmedication
and other relevant history was collected and analyzed.
Results:Datacollected from4763patientswasanalyzed.Meanageof
the populationwas 55 yearswith 59.25%males. Common indication
for the FDCwas uncontrolled hypertension (60.74%).Weaknesswas
themost common event reported (0.29%), followed by pedal odema,
dizziness persistent hypertension 0.27%, 0.23%, 0.23%, respectively.
Less common events reported were Headache (0.08%), gastritis
(0.06%), stroke (0.06%), chest pain (0.04%), LRTI (0.04%), myalgia
(0.04%). Diarrhea, Labyrinthitis, Itching, UTI, Hyponatremia, hypo-
tension and hypersomnia was seen in 0.02% patients. Events were
more common in patientswith uncontrolled hypertension (60.74%).
In other associated conditions diabetes and dyslipidemia was pre-
sent in 37.90% and 35.10% respectively, 15.33% showed both
together. Concomitant statins, hypoglycemic and antiplatelet
agents were prescribed 42.26%, 33.67%, 24.69% respectively.
Conclusions: The FDC of Olmesartan, Amlodipine and Hydro-
chlorothiazide was found to be safe and well tolerated when
prescribed in patients for the management of hypertension.
Prevalence of hypertension in school going
children in Delhi
R.K. Gujju, S. Padmavati, V. Sharma, A.P. Arora, L.C. Gupta
National Heart Institute, New Delhi, India
Aims: The present study was designed to estimate the prevalence
of hypertension among primary school children in Delhi.
Methods: The study was conducted at National Heart Institute,
New Delhi and 10 primary schools of Delhi. All schools were co-
education schools. The ages of children were from 5 to 15 years. A
total of 2011 students were examined for blood pressure (BP) and
anthropometry. Appropriate size BP cuff was used. Pre-hyperten-
sion was defined as Systolic blood pressure (SBP) and/or Diastolic
blood pressure (DBP) between 90th and 95th percentile. Hyperten-
sion was defined as SBP and/or DBP over 95th percentile. Children
having hypertension in first and second recording; repeat mea-
surement was done to confirm hypertension after a week.
Results: The mean age of students was 10.78 ± 2.98 years, mean
height was 141.49 ± 16.38 cms, mean SBP was 103.34 ± 9.0 mm Hg
and mean DBP was 65.97 ± 6.64 mm Hg. Prevalence of obesity in
hypertensives was 8.7% against normotensive 1.1% (p<0.05).
Prevalence of hypertension in family members of hypertensive
was 18.6% and in normotensive 13.1% (p¼0.1). Prevalence of dia-
betes mellitus in family members of hypertensive was 23.4% and
13.7% in normotensive (p<0.05); while prevalence of ischemic
heart disease in family members was 12.34% in hypertensive and
8.3% in normotensive (p<0.05).The prevalence in boys was 3.3% (5-
9 years 2.3%, 10-12 years 4.6%, and 13-15 years 2.9%) and in girls
was 2.9% (5-9 years 2.5%, 10-12 years 2.8%, 13-15 years 3.4%). The
overall prevalence of high BP in school going children of 5-15 years
age was 3.1% (63/2011).
Conclusions: Prevalence of hypertension in school children was
3.1%. We observed obesity, family history of diabetes mellitus,
ischemic heart disease to be significant association for childhood
hypertension.
Effect of cilnidipine on blood pressure, heart rate
and proteinuria in comparison with amlodipine
R.K. Sanap, Sandesh Prabhu, Sanjay Shivapure, N.O. Bansal
JJ hospital, Mumbai, India
Background: Calcium antagonists are now widely used for the
treatment of various types of hypertension. Hypertension is a
widespread public health problem and a major risk factor for
cardiovascular and cerebrovascular diseases. Despite their
ability to lower the high blood pressure effectively, calcium
antagonists do not always protect against cardiovascular com-
plications. Amlodipine used as antihypertensive for long period.
Cilnidipine has two actions, block L-type Ca channels in
vascular smooth muscle, which exerts an antihypertensive ef-
fect similar to L-type Ca channel blockers (e.g., amlodipine), and
block N-type Ca channels at sympathetic nerve endings, which
suppresses increased sympathetic activity in animal models
and human.
We compare the clinical effectiveness of Amlodipine and Cil-
nidipine on blood pressure, heart rate, and proteinuria
Method: The studywas prospective, randomized open lable study.
Total 50 patients were included in study of that 24 patient were on
cilnidipine 10-20 mg and amlodipine 5-10 mg. 12 patients of
amlodipine group and 16 patients of cilnidipine group were dia-
betic. 10 and 12 patients of amlodipine and cilindipine group had
proteinuria respectively. Both groupwere followed for 6months at
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monthly interval for blood pressure and heart rate and proteinuria
was assessed at six month.
Results: Both the groups were well matched in term of sex, age,
and weight. Both cilnidipine and amlodipine significantly reduced
both systolic and diastolic blood pressure. Pulse rate were higher
in patient treated with amlodipine than the patient treated with
cilnidipine. Cilnidipine decreased proteinuria which was not seen
in patient on amlodipine.
Conclusion: Thus, study showed that cilnidipine which is Land N
type calcium channel inhibitor is better than amlodipine which L
type of calcium channel inhibitor in patient having cardiovascular
disease, diabetes and renal disease and is better alternative to
amlodipine.
Effect of permanent pacing VVI mode in patients
with complete heart block on central aortic
pressure and stiffness
R. Bathri Narayanan, M.S. Ravi, K. Meenakshi, D. Muthukumar,
N. Swaminathan, G. Ravishankar, G. Justin Paul,
D. Ramachandran, G. Selvarani, S. Venkatesan
Madras Medical College, Chennai, India
Background: Complete Heart Block (CHB) is a condition in which
the impulse generated in the SA node does not propagate to the
ventricles. Causes include coronary ischemia, idiopathic degen-
eration of AV node and others. Symptomatic patients were
advised Permanent pacemaker insertion. Most have high blood
pressure as per Marey’s law (1961).
Aim: To assess the effect of permanent pacing VVI mode in CHB
patients on central systolic pressure, pulse pressure and arterial
stiffness and to assess the effect of vasodilator therapy in reducing
arterial stiffness in CHB patients on Permanent pacing VVI mode.
Methods: This study is a prospective analytical study done in
Department of Cardiology at single-centre tertiary care hospital
setting from January 2014 to July 2014. 18 consecutive patients
with CHB before and after permanent pacemaker (VVI mode)
insertion were included. Baseline characteristics like Brachial
Systolic Blood Pressure (SBP), Central SBP, Central pulse pressure
(PP), Augmentation pressure (AP), Augmentation Index(AI) and
Heart Rate were measured before and 10 days after pacemaker
insertion. Brachial SBP was measured with Sphygmomanometer
and Central Pressure and stiffness measured using Sphygmocor
device (Excel) which derives central parameters by FDA approved
transfer function. Data were presented as mean ± 1SD and the
characteristics were compared using t test. A p value of less than
0.05 was considered statistically significant. Diabetic patients
were excluded from study.
Results: Out of 18 Patients, mean age was 59yrs (lowest 27yrs and
highest 80yrs), 11 were males and 7 were females.
Conclusion: Insertion of Permanent Pacemaker Insertion VVI
mode shows significance reduction in Central systolic pressure
and arterial stiffness. Based on Central Blood Pressure and Arterial
stiffness assessment some patient needed vasodilators to reduce
arterial stiffness after Permanent pacing.
Use of angiotensin receptor blockers for the
treatment of hypertension in India
H.S. Malhi
Medical Services, Ranbaxy Laboratories Ltd., Mumbai, India
Background: ARBs have been included as a first-line therapy in JNC
8. Additionally, the 2014 ASH/ISH guidelines recommend that ARBs
shouldbepreferredoverACE-I if theyareavailable andaffordable as
they do not cause cough and only rarely cause angioedema, and
haveeffects andbenefits similar toACE-I.Currently there isadearth
of data regarding the use of ARBs as monotherapy or combination
therapy for the treatment of hypertension in India.
Methods: A prescription research survey was conducted amongst
physicians in India to obtain insights about the use of ARBs and
their combinations in clinical practice. The study was conducted
through a survey questionnaire consisting questions on use of
ARBs as an antihypertensive, including preferences of molecules
amongst the ARBs and the combinations of ARBs used for the
management of hypertension with/without comorbid conditions.
Results: The survey questionnaire was answered by 409 physi-
cians. ARBs are preferred as the first-line antihypertensive in
Baseline After treatement
Amlodepine(n-24) Cilnidipine(n-26) Amlodepine(n-24) Cilnidipine(n-26)
Age yrs 58+-4 62+-5
BMI 26+-4 24+-2.6
Number with DM 12 14
Number with proteinuria 10 12
Day time SBP 164+-12 166+-14 152+-10 154+-11
Day time DSP 96+-8 100+-10 88+-8.4 91+-6.2
Day time PR 74+-9.8 72+-7.2 78+-7 64+-4
Night time SBP 140+-18 144+-16 132 +-12 136+-10
Night time DBP 92+-6.4 94+-8.4 88+-6 90+-8
Night time PR 60+-7 64+-8.4 66+-14 60+-8
Characteristics Pre Post PPI P Value
Brachial SBP 157 ± 18.6 122.8 ± 16.96 <0.0001
Central SBP 143 ± 14.37 111 ± 14.53 <0.0001
Central PP 63.9 ± 16 38.11 ± 11 <0.0001
AP 21.56 ± 7.22 10.22 ±5.73 <0.0001
Al 41.4 ± 9.16 24.05 ± 9.9 <0.0001
Pre PPI Pre Brachial VS Central SBP <0.05
Post PPI Post Brachial VS Central SBP <0.04
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